- Home
- MUE vs NVRO Comparison
MUE vs NVRO Comparison
Compare MUE & NVRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUE
- NVRO
- Stock Information
- Founded
- MUE 1999
- NVRO 2006
- Country
- MUE United States
- NVRO United States
- Employees
- MUE N/A
- NVRO N/A
- Industry
- MUE Investment Bankers/Brokers/Service
- NVRO Medical/Dental Instruments
- Sector
- MUE Finance
- NVRO Health Care
- Exchange
- MUE Nasdaq
- NVRO Nasdaq
- Market Cap
- MUE 223.1M
- NVRO 221.2M
- IPO Year
- MUE N/A
- NVRO 2014
- Fundamental
- Price
- MUE $10.02
- NVRO $5.85
- Analyst Decision
- MUE
- NVRO Hold
- Analyst Count
- MUE 0
- NVRO 12
- Target Price
- MUE N/A
- NVRO $7.24
- AVG Volume (30 Days)
- MUE 62.6K
- NVRO 1.3M
- Earning Date
- MUE 01-01-0001
- NVRO 03-04-2025
- Dividend Yield
- MUE 4.09%
- NVRO N/A
- EPS Growth
- MUE N/A
- NVRO N/A
- EPS
- MUE N/A
- NVRO N/A
- Revenue
- MUE N/A
- NVRO $408,518,000.00
- Revenue This Year
- MUE N/A
- NVRO $1.55
- Revenue Next Year
- MUE N/A
- NVRO $4.36
- P/E Ratio
- MUE N/A
- NVRO N/A
- Revenue Growth
- MUE N/A
- NVRO N/A
- 52 Week Low
- MUE $8.53
- NVRO $3.17
- 52 Week High
- MUE $10.17
- NVRO $14.43
- Technical
- Relative Strength Index (RSI)
- MUE 42.40
- NVRO 70.78
- Support Level
- MUE $9.94
- NVRO $5.77
- Resistance Level
- MUE $10.45
- NVRO $5.81
- Average True Range (ATR)
- MUE 0.12
- NVRO 0.03
- MACD
- MUE -0.01
- NVRO -0.02
- Stochastic Oscillator
- MUE 19.44
- NVRO 100.00
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.